Trident Texofab has informed that pursuant to the provisions of Regulation 32(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations) the Company enclosing herewith the statement of deviation or variation in public issue, rights issue, preferential issue etc. for the quarter ended on December 31, 2019.
The above information is a part of company’s filings submitted to BSE.